Mednet Logo
CommunityMedical Oncology

For mCRPC patients who are eligible for both, how do you decide between Enzalutamide+Rad223 (EORTC 1333/PEACE-3) or Enzalutamide+Lu-PSMA-617 (ENZA-p)?

Gillessen et al., PMID 41763609
Community PollStarted

Which radionuclide therapy do you prefer to initiate first for patients with bone-only metastatic CRPC?

143 physicians have voted

Join Mednetto vote and see how they answered.

1 Answer
Mednet Member
Mednet MemberInvited Expert
Medical Oncology · University of Virginia
Answered on

While both these studies addressed interesting questions, both enrolled patients who were ARPI-naive. We are in an era where ADT intensification is the standard of care, and hopefully, we will see an even smaller number of folks with mCRPC who would look like the patients enrolled in both these stud...

Join for free or sign in to see the full answer